| :: transition therapeutics |
On January 17, 2002, Transition Therapeutics Inc. (CDNX: TTH) and Waratah Pharmaceuticals Inc. (CDNX: WAR) completed their merger. The businesses and
Results 1 - 17 of 17 SC 13G/A, TRANSITION THERAPEUTICS INC. (FEINBERG LARRY N), 12/08/11. SC 13G/A, TRANSITION THERAPEUTICS INC. (FMR LLC)
Get the latest TTHI - Transition Therapeutics Inc. earnings, stock market performance data and financial news.
EV/EBITDA ratio of Transition Therapeutics (CA8937162094 - TTH) and its peer group for financial analysis.
Results 1 - 21 Reports the approval received by Transition Therapeutics Inc. to conduct the first phase of trials of its islet neogenesis therapy in Great Britain.
Transition Therapeutics (TTHI) stock quote, charts, historical data, financials.
Transition Therapeutics, Inc. Address: Toronto, Ontario, CA
22, 2011 -- Transition Therapeutics Inc. today announced the closing of its previously disclosed private placement financing issuing.
The Transition Therapeutics Inc. (TTHI) Competitors by Product report shows Transition Therapeutics Inc. products and services according to the actual sector or
TORONTO, Dec. 9, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ( Transition) (TSX:TTH) (Nasdaq:TTHI) today announces that Mr.
Message Boards: TTHI (Transition Therapeutics). Tweet This · chart · TTHI ( Transition Therapeutics - Msgs, Twts, Profile). Last: 1.30 -0.02 (-1.52%) · Vol: 19832
Transition Therapeutics inc.†. Diane Paul,; Philémon Rakoto. Article first published online: 21 JAN 2010. DOI: 10.1506/ap.7.2.6. 2008 Canadian Academic
TORONTO, August 30, 2007 PRNewswire-FirstCall - Transition Therapeutics Inc. ( Transition ) announced today the completion of Phase I
Transition Therapeutics Announces US$5 Million Private Placement.
US:TTHI - Get Stock quote detail for Transition Therapeutics Inc. Stock quotes include the latest US:TTHI market price and fundamental investing data,
Transition Therapeutics (Transition) is a Canadian based biopharmaceutical company, engaged in developing novel therapeutics for disease
TORONTO, Dec. 12, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ( Transition) (TSX:TTH) today announces the appointment of Ms.
Transition Therapeutics' detailed financials; Comprehensive pipeline breakdown, including molecular targets & partnerships. 17 years of in-depth BioPharma
SC 13G/A - Transition Therapeutics Inc - On 2/8/11 - EX-99.1 - Statement of Beneficial Ownership - Seq. 2 - Joint Filing Agreement - Accession
12, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition") (TSX: TTH) today announces the appointment of Ms. Nicole
7, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the " Company") (TSX:TTH) (Nasdaq:TTHI), a product-focused
News for Medical Sales & Marketing professionals and Independent Sales Representatives: Transition Therapeutics Announces the Departure
Transition Therapeutics Inc. Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a
Health care industry insiders provide analysis & data on pharma biotech device & diagnostic company strategy & trends. Deals & technology
Transition Therapeutics (TTHI) Promotes Nicole Rusaw-George to CFO Dec Transition Therapeutics announces initiation of TT-401 Phase l
LifeSci Advisors Announces Investment Opinion on Transition Therapeutics, Inc. Transition Therapeutics shrinks yearly loss to 19.3M; revenue up 79 per cent
A good President's Day for Transition Therapeutics (TTHI). On Monday the company posted an unexpected profit for the second quarter,
Free Online Library: Transition Therapeutics Enhances Intellectual Property Portfolio For Its Multiple Sclerosis Program. by "PR Newswire";
Transition Therapeutics Inc. company profile,Transition Therapeutics Inc. Address:101 College St., Ste. 220 TorontoON M5G 1L7 Canada,Website:, Contact
DUBLIN & TORONTO -- Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (TSX: TTH, NASDAQ:TTHI) today announced the
Transition Therapeutics Inc. (TTHI) - Financial and Strategic Analysis Review - new company profile and swot report published Transition
featured press releases, both from Transition Therapeutics Inc. and Review of current pipeline of Transition Therapeutics Inc. human therapeutic division.
Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company developing therapeutics for disease indications with
TORONTO, Sep 17, 2010 -- Transition Therapeutics Inc. /quotes/comstock/15*!tthi /quotes/nls/tthi /quotes/comstock/11t!e:tth announced today
Transition Therapeutics Inc. (TTH) - Financial and Strategic SWOT Analysis Review, published August 2011, pages 25, Transition Therapeutics Inc. ( Transition
Business Editors & Health/Medical Writers BIOWIRE2K TORONTO--(BUSINESS WIRE)--Nov. 27, | Article from Business Wire November 27, 2002.
Transition Therapeutics reported it will halt development of an experimental type 2 diabetes drug, TT-223, being developed with Eli Lilly after a
TORONTO, April 3 /CNW/ - Transition Therapeutics Inc. ("Transition") (TSX: TTH) announced today that the United States Food and Drug
Transition Therapeutics Toronto (TSX): TTH. Regenerative therapy for diabetes and small-molecule drug against Alzheimer's disease
27, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq: ) announced that Phase 2
Transition Therapeutics is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets.
Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX: TTH) will hold a conference call on Thursday, December 1,
Transition Therapeutics Licenses Diabetes Regenerative Therapy to Novo Nordisk A/S.
DUBLIN, Ireland & TORONTO -- Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (NASDAQ: TTHI, TSX: TTH) today
Elan and Transition Therapeutics inked an exclusive, worldwide collaboration agreement for the joint development and commercialization of a
TORONTO, Sep 27, 2011 (GlobeNewswire via COMTEX News Network) -- Transition T.
Transition Therapeutics Inc. 415 Yonge Street Suite 1103. Toronto Ontario M5B2E7 Canada Phone: 416-260-7770 Fax: 416-260-2886. SEARCH JOBS
Transition Therapeutics Appoints New Chief Financial Officer.
Transition Therapeutics, Inc. ( NASDAQ: TTHI ) ( TSX: TTH ); Transition Therapeutics, Inc. Home. Partner : Elan Corporation. ELND005 (AZD-103) for Alzheimer's
Transition Therapeutics Announces US Million Private Placement.
Transition Therapeutics, Inc. is a biopharmaceutical company that develops novel Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is
Symbol: tthi, Name: Transition Therapeutics Inc., Title: Transition Therapeutics Inc . (TTHI) Stock Quote.
Transition Therapeutics Acquires Certain Assets of Forbes Medi-Tech (Research)
TORONTO, July 15, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. (
Transition Therapeutics Inc company profile in Toronto, Canada. Our company profile report for Transition Therapeutics Inc includes business information such
Q1 2012 Earnings Call - Transition Therapeutics, Inc., - Call Street Report.
Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (NASDAQ: TTHI, TSX: TTH) today announced that the first patient has been
Free article about 'Elan Pharmaceuticals pays Transition Therapeutics Inc $9 M in amended deal for Phase II alzheimer.
27, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) announced that Phase
Just because a drug has managed to successfully meet earlier trial goals, it's no guarantee it will continue to do so. On Tuesday, Gilead, Elan
Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company, developing therapeutics for disease indications with large markets.
September 27th, 2011 - Transition Therapeutics Inc. ("Transition" or the " Company") (TSX: TTH, NASDAQ:TTHI) announced that Phase 2
Transition Therapeutics Completes US$5 Million Private Placement.
Results 1 - 20 of 105 TRANSITION THERAPEUTICS INC.: TTHI (Nasdaq Global
Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH.TO) ( Nasdaq:TTHI), a product-focused biopharmaceutical company
Transition Therapeutics has a R&D Expense of 2.19M. Transition Therapeutics R&D Expense (TTHI) charts, historical data, comparisons and
Transition Therapeutics reaches a turning point Nearly ten years after launching Transition Therapeutics, veteran entrepreneur and scientist
Transition Therapeutics has a Market Cap of 33.44M. Transition Therapeutics Market Cap (TTHI) charts, historical data, comparisons and more.
Transition Therapeutics Inc., a biopharmaceutical company, has announced that the first patient has been dosed in a Phase I clinical study of
Transition Therapeutics (TSE:TTH) (NASDAQ:TTHI) said Tuesday that positive phase-two clinical study data for its small molecule drug
Credit & Investment Research, Thomson StreetEvents: TRANSITION THERAPEUTICS INC Q4 2010 Earnings Conference Call Transcript
Hoovers company profile of Transition Therapeutics Inc.. Find detailed business information such as key executives, financials and other corporate data on
Get the latest index performance and chart outlook for TRANSITION THERAPEUTICS INC. (TTH.TO).
TORONTO, Nov. 5 /PRNewswire-FirstCall/ -- Transition Therapeutics Inc. (" Transition" or the | Article from PR Newswire November 5, 2007.
Transition Therapeutics (NASDAQ:TTHI) is a development stage biopharmaceutical based in Toronto, Canada. This is a very small company
Free Business profile for TRANSITION THERAPEUTICS INC at 101 COLLEGE TRANSITION THERAPEUTICS INC specializes in: Medicinal Chemicals and
Transition Therapeutics Inc. - Product Pipeline Review - Q1 2011, Transition Therapeutics Inc. - Product Pipeline Review - Q1 2011 Summary Global Market
Transition Therapeutics Inc. (TTHI) Thursday reported a net loss of C$2.9 million or C$0.12 per share, narrower than the loss of C$3.5 million or
Transition Therapeutics Commences Phase I Human Trial For I.N.T(TM) Dr. Tony Cruz, Chairman and CEO of Transition, said that the
Transition Therapeutics (Nasdaq:TTHI) has been downgraded by TheStreet Ratings from from a hold to sell..
TRANSITION THERAPEUTICS INC (TTH:CN) stock price & investing information. Find TRANSITION THERAPEUTICS INC historical stock quotes, key
Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2012 Financial Results on Thursday, December 1st, at 4:30 P.M. EST
View Transition Therapeutics Ord TTHI investment & stock information. Get the latest Transition Therapeutics Ord TTHI detailed stock quotes, stock data,
View the latest TTHI - Transition Therapeutics real-time stock quote information. Get detailed breaking investment performances, chart analysis, stock prices,
Latest Transition Therapeutics Share Price and News. Transition Therapeutics has an emerging pipeline of preclinical drug candidates acquired externally and
22, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) today announced the
Financial News - Transition Therapeutics, Inc. (TTHI.O) - Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2010
Transition Therapeutics Inc.(Nasdaq: TTHI) today announced that it has entered into agreements to issue 3703703 common shares at a price of
Transition Therapeutics Inc. Announces First Quarter Fiscal 2003 Financial Results from Business Wire.
Collection of recommend articles and news on Transition Therapeutics, including etc. The latest articles such as: Transition Therapeutics Inc.
Zacks Analyst Blog Highlights: Elan, Transition Therapeutics, Pfizer, Novartis AG, Johnson & Johnson and Forest Laboratories-Zacks Analyst
Get free quotes, charts & company news on Transition Therapeutics.
Transition Therapeutics Inc. (Transition Therapeutics) is a publicly held biopharmaceutical company. The company is engaged in the drug development program
Transition Therapeutics Inc. tth go to snapshot add to favorites. post. see all posts , Overall Quality 2+, Overall Quality 3+, Overall Quality 4+, Overall Quality 5
Transition Therapeutics Inc. financial and business news, updates, and information from The New York Times and other leading providers.
Ellipsis makes deal with Transition Therapeutics on Strategic Transactions, Nov- 01-2004.
Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio tables (Accounting, Asset Utilization,
Get detailed financial information on Transition Therapeutics Inc. (TSE:TTH) including real-time stock quotes, historical charts & financial news, all for free!
New Market Report: Transition Therapeutics Inc. - Product Pipeline Review - Q1 2011.
NeuroMedix receives acquisition offer by Transition Therapeutics. TORONTO, Ontario - March 21, 2007: NeuroMedix Inc. ("NeuroMedix")
Transition Therapeutics USA Inc is located at 11099 N Torrey Pines Rd Ste 230 La Jolla, CA. Phone: 858-626-2930. . Post a message and leave a review for
Transition Therapeutics (USA) Inc. company research & investing information. Find executives and the latest company news.
Global Market Direct's pharmaceuticals report, Transition Therapeutics Inc. - Product Pipeline Review - Q1 2011 provides data on the Transition
menafn: Transition Therapeutics AnnouncesDepartureIts PresidentChief Financial OfficerTORONTO, Dec 9, 2011 (GlobeNewswire via
Company profile, information and contact info for Transition Therapeutics Inc. - 101 College Street, Suite 220, Toronto, ON from ProFile Canada, Canada's most
Business Editors & Health/Medical Writers BIOWIRE2K TORONTO--(BUSINESS WIRE)--Nov. 28, | Article from Business Wire November 28,
Presentations at 2009 Alzheimer s Association International Conference on Alzheimer s Disease Support Ongoing Phase 2 Trial Jul 13, 2009 - Elan Corporation
Stock market news and stock research. Financial news, stock news and stock makrket update about the stocks, ETF and mutual funds listed on the NYSE, AMEX
9, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition") (TSX: TTH) (Nasdaq:TTHI) today announces that Mr. Elie Farah, the
Transition Therapeutics Inc. Company & Business Contact information- Jigsaw Business Directory. Get complete contact & company information with emails and
Transition Therapeutics Inc. - Product Pipeline Review - H2 2011 Transition Therapeutics Inc. - Product Pipeline Review - H2 2011 Summary
BioWorld Online is the news service of record for the biotechnology industry and is updated every business morning. BioWorld Online will keep
Transition Therapeutics Provides Update on Diabetes Program.
Elan Corporation, plc and Transition Therapeutics Inc. announced the achievement of the patient enrollment target for a Phase 2 clinical study
Elan and Transition Therapeutics Announce Modifications to ELND005 Phase II Clinical Trials in Alzheimer's Disease 15.12.2009 | Nachricht
Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2011 Financial Results on Tuesday, May 10th, at 4:30 P.M. EDT
28 /PRNewswire-FirstCall/ -- Transition Therapeutics Inc. ("Transition" or the " Company") (TSX: TTH; NASDAQ: TTHI), is pleased to announce
Forum overview for "TTHI: Message Board for TRANSITION THERAPEUTICS INC " forum on InvestorVillage: Stock Message Boards
Transition Therapeutics Inc. 220-101 College St Toronto, ON M5G 1L7 Tel: (416) 260-7770. Toll-free: (877) 311-5272. Fax: (416) 260-2886. Contact Name
Transition Therapeutics (TTHI) is up after it said late Monday it earned C$1.05 per share in Q2, better than the Thomson Reuters mean for a loss of C$0.02.
Transition Therapeutics to Hold Conference Call on Full Year Fiscal 2011 Financial Results on Monday, September 19th, at 4:30 P.M. EDT
Transition Therapeutics Inc, Premium Company Profile: , published April 2008, pages 46, IntroductionTransition Therapeutics is a biopharmaceutical company,
Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (NASDAQ: TTHI, TSX: TTH) today announced the achievement of the
Transition Therapeutics Announces US$5 Million Private Placement. TORONTO 21, 2011 (GLOBE NEWSWIRE) — Transition Therapeutics
Transition Therapeutics Inc., a biopharmaceutical company, develops novel therapeutics for various disease indications primarily in Canada.
Transition Therapeutics Dose First Patient in Phase 2 Clinical Study of TT-223 in Type 2 Diabetes. TORONTO, Sept. 12 /CNW/ - Transition
Results 1 - 10 of 38 Assignee(s): TRANSITION THERAPEUTICS INC | Inventor(s): CRUZ TONY + 1. TRANSITION THERAPEUTICS INC View patent details for
Says TT-223 fails to show efficacy in study * Says other licensing deal with Eli Lilly stays Sept 17 (Reuters) - Transition Therapeutics Inc (TTH.
Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (Nasdaq: TTHI) today announced the closing of its previously disclosed
Transition Therapeutics Announces First Quarter Fiscal 2008 developing therapeutics for disease indications with large markets, today
Transition Therapeutics IncTSX/Alpha:TTHview on NASDAQ » · Help. Symbol Lookup. No Matches were found for. Additional matches for Go. We've made
Transition Therapeutics Inc. ( Transition or the Company ) (TSX TTH) (Nasdaq TTHI) announced that Phase 2 clinical study data of ELND005 in
Transition Therapeutics Inc. (TTHI), On Jan 10: 1.49 0.00 (0.00%) Please send us feedback. Message Boards Settings Transition Therapeutics Inc.
View the basic TTH.TO stock chart on Yahoo! Finance. Change the date range, chart type and compare TRANSITION THERAPEUTICS INC. against other
Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics. Inc. (TSX: TTH, NASDAQ:TTHI) today announced the United States
menafn: Transition Therapeutics Appoints New Chief Financial OfficerTORONTO, Dec 12, 2011 (GlobeNewswire via COMTEX) --Transition
Transition therapeutics confident of deal with Novo on diabetes treatment. World Heart shuffles top two executives.
Transition Therapeutics (NASDAQ:TTHI) is lowest with an EV/EBITDA ratio of 0.76. Transition Therapeutics Inc. is a biopharmaceutical
Transition Therapeutics Announces Initiation of a Phase 1 Clinical Study of 12, 2011 (GLOBE NEWSWIRE) — Transition Therapeutics Inc.
Global Markets Direct :: Transition Therapeutics Inc. ? Product Pipeline Review ? Q1 2011 :: June 2011 :: Pharmaceutical market research report.
DUBLIN, Dec 15, 2009 (BUSINESS WIRE) -- Elan Corporation, plc and Transition Therapeutics, Inc. today notified clinical investigators of
Transition Therapeutics Inc. Message board - Online Community of active, educated investors researching and discussing Transition
Transition Therapeutics Inc. said Friday its potential type 2 diabetes drug failed in a clinical trial and the company will end development.
The Transition Therapeutics Inc. (TTHI) Company Profile report lists of key business relationships for Transition Therapeutics Inc. are all
Transition Therapeutics Announces Initiation of a Phase 1 Clinical Study of Diabetes Drug Candidate TT-401. TORONTO, Dec 12, 2011
New York and Toronto listed biopharmaceutical company Transition Therapeutics (TSX:TTH, NASDAQ:TTHI) has expanded the number of
On February 26, 2004, Transition Therapeutics announced that it had finished an extended phase 1 clinical trial of therapy with I.N.T. in people with type 1
Dr. Cruz is one of the founders of Transition Therapeutics and has held the position of Chief Executive Officer of Transition Therapeutics since
3/3/2010-Transition Therapeutics (NASDAQ:TTHI) said early Wednesday that it has acquired the rights to a series of diabetes-related
Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman. Matthew R.
Transition Therapeutics Inc. (NASDAQ:TTHI). + Watch TTHI. on My Watchlist. $1.47 0.02 (+1.64%). 1/5/2012 3:33 PM
Transition Therapeutics Inc. - Product Pipeline Review - Q1 2011 Summary Global Market Direct's pharmaceuticals report,
Transition Therapeutics Inc. (NASDAQ: TTHI) is seeing shares surge in after- hours activity. It has signed a pact with Eli Lilly and Co. (NYSE:
{Globe Newswire via BioPortfolio} TORONTO, Sept. 27, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the
Transition Therapeutics Inc. announced a series of actions to strengthen the Company's drug discovery group. Transition has acquired certain
TORONTO, March 3, 2010 -- Transition Therapeutics Inc. today announced that it has acquired the rights to a series of preclinical compounds
Collection of recommend articles and news on Transition Therapeutics Inc, including etc. The latest articles such as: Transition Therapeutics
20, 2002 Transition Therapeutics Inc. ("Transition") (TSX VENTURE:TTH) today announced that it has commenced a Phase I human trial of its
27/04/2006 - Transition Therapeutics Receives Clearance to Initiate Phase I Clinical Trial with Alzheimer's Disease Product AZD-103. Attention Business Editors
TORONTO, Dec. 1, 2011 -- Transition Therapeutics Inc. , a product-focused biopharmaceutical company developing therapeutics for disease
Transition Therapeutics Inc. (NASDAQ: TTHI) today announces the appointment of Ms. Nicole Rusaw-George, C.A., as Chief Financial Officer of
Transition Therapeutics Inc. Message board - Online Community of active, educated investors researching and discussing Transition Therapeutics Inc. Stocks.
Free Online Library: Elan and Transition Therapeutics Announce Modifications to ELND005 Phase II Clinical Trials in Alzheimer's Disease. by
Goliath's Transition Therapeutics Inc. Company Profile provides detailed company information on Transition Therapeutics Inc. located in
Transition Therapeutics (through its acquisition of Waratah Pharmaceuticals), in collaboration with Novo Nordisk, is developing E1-INT, an injectable islet
Transition Therapeutics Announces Initiation of a Phase 1 Clinical Study of Diabetes Drug Candidate TT-401 - Dec 12, 2011. © 2011 Transition Therapeutics
Elan and Transition Therapeutics also ran into trouble with ELN-0005, their partnered anti-aggregation agent. The top two doses (1000mg and 2000mg BID)
Elan And Transition Therapeutics Announce Topline Summary Results Of Phase 2 Study and Plans for Phase 3 for ELND005 (Scyllo-inositol )
Transition Therapeutics Announces ELND005 Phase 2 Clinical Trial Data to bePresented at the International Conference of Alzheimer's
Versant Partners has downgraded Transition Therapeutics (TSX:TTH; NASDAQ: TTHI) to “neutral” from “buy” and slashed its price target to $3.25 from $6.25,
Finance: TORONTO -- Transition Therapeutics Inc. ("Transition") today announces that Mr. Elie Farah, the Company's President and Chief
Transition Therapeutics Inc. (TTHI, TTH.T) agreed to sell 3.7 million shares in a private placement at a 16% discount to Friday's close to raise
Transition Therapeutics Inc. (Nasdaq: TTHI) reports that the first patient has been dosed in a Phase 1 clinical study of type 2 diabetes drug
Transition Therapeutics (Nasdaq: TTHI) today announced that it has entered into agreements to issue 3703703 common shares at a price of
Transition Therapeutics Inc. has announced the appointment of Nicole Rusaw- George as its CFO.
Preview and download documents about transition therapeutics
Highlights include Patheon raising $280 million from its note placement, Verio Therapeutics getting phagocytosed by Fate (but remaining in Ottawa) and Lorus
Company profile for Transition Therapeutics. Includes latest key event, news and commentary, top selling products, worldwide prescription sales, sales by
Transition Therapeutics Inc. (TTHI) shares were up almost 5% Friday morning as investors react positively to an announced collaboration with
INFO) - June 5, 2007 - Transition Therapeutics Inc. (TSX: TTH) announced today that it has filed a Registration Statement on Form 40-F
Our research team will bring you any news or updates about Transition Therapeutics Inc. as they come into the public realm in the coming
Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company, developing therapeutics for disease indications with
Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX: TTH) announced today the first patient has been dosed in a
Q2 EPS C$1.05 vs est C$0.02 loss/share * Q2 rev at C$29.7 mln vs C$987828 year ago * U.S.-listed shares up 7 pct after market (Recasts,
TORONTO, Nov. 22, 2011 -- Transition Therapeutics Inc. today announced the closing of its previously disclosed | November 23, 2011.
Transition Therapeutics Announces Positive Data from E1-I.N.T." Clinical Trials in JDRF Partners With Transition Therapeutics Inc. to Develop a Beta Cell
Get detailed financial information on Transition Therapeutics Inc (NASDAQ:TTHI) including real-time stock quotes, historical charts & financial news, all for free!
Get Transition Therapeutics Inc. business contacts for
Elan paid Transition Therapeutics $9 million in January 2011 and is In August 2010, Elan and Transition Therapeutics had reported data on
Transition Therapeutics Inc. (Transition Therapeutics) is Canada based health care biopharmaceutical company. The organization is involved in the medicine
Transition Therapeutics Inc.: News Release [February 22, 2011 - 08:10 AM PST]: Feb. 22, 2011 (GlobeNewswire) -- TORONTO, Feb. 22, 2011
Up to date analysis of Transition Therapeutics, Inc. (TTHI) and its stock by hedge fund managers and industry experts. Find out what Transition Therapeutics, Inc.
Transition Therapeutics Completes US$5 Million Priv.
Transition Therapeutics Inc., a biopharmaceutical company, has reported that net loss and comprehensive loss for the first quarter ended
DUBLIN & TORONTO --(BUSINESS WIRE)--Apr. 23, 2009-- Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (TSX: TTH,
TORONTO, Dec 9, 2011 (GlobeNewswire via COMTEX) -- Transition Therapeutics Inc. ("Transition") /quotes/zigman/39571 CA:TTH -15.38%
Transition Therapeutics (TTHI) is up after it said late Monday it earned C$1.05 per share in Q2, better than the Thomson Reuters mean for a
5 /PRNewswire/ - Transition Therapeutics Inc. (CDNX: TTH) announced today that it has acquired the intellectual property to Biogenesys' methlydonor
Transition Therapeutics Inc. (NYSEAMEX:TTHI) is a product-focused biopharmaceutical company developing therapeutics for disease
TORONTO, March 21 - - Transition Therapeutics Inc. ("Transition") (TSX: TTH) announced today that it has signed an agreement to offer to purchase all of the
Find financial news for Transition Therapeutics Inc. (NYSEAMEX:TTHI) using Google Finance.
TRANSITION THERAPEUTICS. January 27, 2004. Clinical-stage biotech with potential breakthrough therapy for diabetes. All values in C$ unless otherwise
Canada's Transition Therapeutics says that it has acquired the rights to a series of preclinical compounds from US drug major Eli Lilly in the
21, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc.("Transition" or the "Company") (TSX:TTH) (Nasdaq:TTHI) today announced that it
Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations. TORONTO, June 18 /CNW/ - Transition Therapeutics
Transition Therapeutics Inc. ("Transition") to acquire all of the outstanding shares of NeuroMedix. "This deal with Transition represents good value for our
T.TTH Transition Therapeutics Inc. Transition Therapeutics Announces First Quarter Fiscal 2012 Financial Results 12/1/2011 4:01:28 PM - GlobeNewswire
Transition Therapeutics is focused on the research and development of products primarily for the treatment of central nervous system (CNS) and metabolic
Deal builds on existing collaboration focused on Transition's clinical-stage gastrin-based drugs.
TORONTO, CANADA -- June 12, 2006 -- Transition Therapeutics Inc. announced that Nature Medicine, one of the world's leading peer reviewed medical
Results 1 - 7 of 10 Transition Therapeutics Announces Initiation of a Phase 1 Clinical Study of Transition Therapeutics Appoints New Chief Financial Officer
Transition Therapeutics Inc. announced that the first patient has been dosed in a Phase 2 clinical study of gastrin analogue, TT-223.
Transition Therapeutics announces that Mr. Elie Farah, the company's President and Chief Financial Officer, has left the Company to pursue new challenges.
Transition Therapeutics Receives Anniversary Payment from Stem Cell To date , Transition has received $800000 in cash payments and is
Transition Therapeutics. transitiontherapeuticslogo www.transitiontherapeutics. com. Get More From MaRS, MaRS NEWSLETTERS. Facebook Twitter Vimeo
AIM Therapeutics Advances Asthma Therapeutics Program AIM Therapeutics Inc. NeuroMedix was acquired by Transition Therapeutics in March 2007.
Global Markets Direct :: Transition Therapeutics Inc. Product Pipeline Review H2 2011 :: September 2011 :: Pharmaceutical market research report.
Transition Therapeutics Inc. is a publicly traded biopharmaceutical company developing novel approaches and therapeutics for the treatment of diabetes,
Transition Therapeutics Announces Third Quarter Fiscal 2010 Financial Results TORONTO -- Transition Therapeutics Inc. , a product-focused
Transition Therapeutics Announces Initiation of a Phase 1 Clinical Study of Transition Therapeutics Announces the Departure of Its President and Chief
By Christopher P. Singer Transition Therapeutics, Inc. announced in an April 3, 2007 press release that its investigational Alzheimer's disease
Stock analysis for TTHI:US. Get stock price, historical stock charts & news for Transition Therapeutics Inc, in the Therapeutics industry.
Transition Therapeutics Inc. Message board - Online Community of active, educated investors researching and Transition Therapeutics Inc.
Anti-diabetes compounds. ALZHEIMER'S DISEASE TYPE 2 DIABETES /
Transition Therapeutics - (Canada) Ordinary Shares Stock Quote, News, Stock Chart, SEC Filings NASDAQ Stock Market TTHI.
Transition Therapeutics Inc. - Product Pipeline Review, H2 2011: , published September 2011, pages 54, Transition Therapeutics Inc. - Product Pipeline Review
Company profile for Transition Therapeutics Inc. in Toronto,ON. Get accurate business information including key contacts, company financials and more in the
M of Transition Therapeutics Inc (TTHI) stock bought by Jack Schuler.
Transition Therapeutics completes private placement. print; bookmark; archives Transition Therapeutics Inc. (TSX:TTH. 4 words displayed of
Transition Therapeutics Inc. (Symbol:TTH) SWOT Analysis, Strategy, Revenues and Profits, This report is systematically updated by our analysts for each new
Transition Therapeutics would like to help people suffering from disease to make the transition to good health. The biotechnology firm is working on therapies to
Read about how life science organizations have benefited from doing business in Toronto.
Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2012 Financial Results on Thursday, December 1st, at 4:30 P.M. EST.
TORONTO, Sep 19, 2011 (GlobeNewswire via COMTEX News Network) -- Transition Therapeutics Inc. ("Transition" or the "Company")
No Hype - No Ads Just the Facts. Your complete source of news and realtime quotes from the TSX, TSX-V, Montreal, Nasdaq, NYSE, Amex,
Review and download historical prices and charts for Transition Therapeutics Inc. (NYSEAMEX:TTHI).
News for Medical Sales & Marketing professionals and Independent Sales Representatives: Lilly and Transition Therapeutics Announce
Transition Therapeutics Inc. Announces Initiation Of Phase 1 Clinical Study Of Transition Therapeutics Inc. announced that the first patient has been dosed in
Stock quote for Transition Therapeutics, Inc. (TTHI) - Get real-time last sale and extended hours stock prices, company news, charts, and
Transition Therapeutics Inc. is a Canadian biopharmaceutical company developing novel approaches and therapeutics to inhibit inflammatory and fibrotic
Transition Therapeutics Inc. stock price today: (TTHI) stock quote, price history, earnings per share, technical analysis chart and breaking news.
Elan Corporation, plc and Transition Therapeutics, Inc. notified clinical investigators of modifications to the Phase II study AD201 and open
Transition Therapeutics Inc. 101 College Street Suite 220,
Sponsor: Transition Therapeutics. Information provided by: Transition Therapeutics. ClinicalTrials.gov Identifier: NCT01357421
Transition Therapeutics Inc. - Product Pipeline Review - Q1 2011 Transition Therapeutics Inc. - Product Pipeline Review - Q1 2011 Summary
9, 2011 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc.("Transition" or the " Company") (TSX:TTH) (Nasdaq:TTHI) announced today that
Transition Therapeutics to Trade on NASDAQ Capital Market.
Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2011 Financial Results on Monday, February 7th, at 4:30 P.M. EST
The directory is an ongoing effort by CanBiotech to profile all North American, U.K., German, France, Netherlands, Indian, Taiwan and other emerging biotech
Take a look at TTHI if you are looking for a stock with deep meaning to it.
Through its Industry Discovery and Development Partnership Program, JDRF is providing Transition Therapeutics funding over two years for
TRANSITION THERAPEUTICS INC.(TTHI)SEC FILINGS. View all filings and insider trading for TRANSITION THERAPEUTICS INC..
Transition Therapeutics (TTHI) and Elan (ELN) Modify ELND005 Development Transition Therapeutics shrinks yearly loss to 19.3M; revenue up 79 per cent
Elan Pays Transition $9M in Amended Deal for Phase II Alzheimer Candidate · Transition Therapeutics and Lilly Expand Diabetes Partnership through
News for Medical Sales & Marketing professionals and Independent Sales Representatives: Transition Therapeutics Announces Executive
Transition Therapeutics gets $9.45mm in private investments on Strategic Transactions, Feb-01-2006.
Transition Therapeutics, Inc. (NASDAQ:TTHI) Hear what millions of investors are saying now about Transition Therapeutics, Inc. with
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced
TORONTO, Sep 19, 2011 (GlobeNewswire via COMTEX) --Transition Therapeutics Inc. (Transition or the Company) /quotes/zigman/39571
Report Cites Planned ELND005 Phase 3 in Alzheimer's, TT401/TT402 Dual GLP- 1 Agonists for Type 2 Diabetes and TT301/302 for
2011-12-31 TTHI: Transition Therapeutics Inc Institutional Investments! Transition Therapeutics Inc dumped -74633 shares, change of -100% to total position of
Since acquiring Protana in November 2005, Transition Therapeutics has been using the company s Optimol technology to identify small
Latest Transition Therapeutics Share Price and News. A biopharmaceutical company developing novel therapeutics.
Transition Therapeutics Inc. ("Transition") (TSX:TTH) today announces the appointment of Ms. Nicole Rusaw-George, C.A., as Chief Financial
Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement. Lilly to Acquire Exclusive Rights to Gastrin Based
Elan and Transition Therapeutics Inc. Announce Global Collaboration to Develop and Commercialize Alzheimer's Disease Drug AZD-103 from
Transition Therapeutics Sells 3.7M At 16% In Private Deal. Subscriber RehabCare Group, Transition Therapeutics: Biggest Price Gainers (RHB, TTHI). Feb 8
Up to date news for the parmaceutical and biotechnology industries.
Name: